Early Diagnosis and Outcome in Patients With Wild-Type Transthyretin Cardiac Amyloidosis.

[1]  C. Rapezzi,et al.  A new therapy for transthyretin amyloidosis, no longer an orphan condition , 2020, European heart journal supplements : journal of the European Society of Cardiology.

[2]  H. Vase,et al.  Diagnostic delay in wild type transthyretin cardiac amyloidosis - A clinical challenge. , 2020, International journal of cardiology.

[3]  J. Gurwitz,et al.  Tafamidis-A Pricey Therapy for a Not-So-Rare Condition. , 2020, JAMA cardiology.

[4]  G. Parati,et al.  Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy. , 2020, International journal of cardiology.

[5]  M. Emdin,et al.  Treatment of cardiac transthyretin amyloidosis: an update. , 2019, European heart journal.

[6]  C. Rapezzi,et al.  Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. , 2019, Circulation. Heart failure.

[7]  A. Petrie,et al.  Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. , 2019, Circulation.

[8]  F. Domínguez,et al.  Prevalence of cardiac amyloidosis among elderly patients with systolic heart failure or conduction disorders , 2019, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[9]  M. Maurer,et al.  Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. , 2019, Journal of the American College of Cardiology.

[10]  F. Dominici,et al.  Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States. , 2019, Circulation. Heart failure.

[11]  P. Kyriakou,et al.  Diagnosis of cardiac amyloidosis: a systematic review on the role of imaging and biomarkers , 2018, BMC Cardiovascular Disorders.

[12]  Sanjiv J. Shah,et al.  Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy , 2018, The New England journal of medicine.

[13]  A. Petrie,et al.  A new staging system for cardiac transthyretin amyloidosis , 2018, European heart journal.

[14]  M. Halushka,et al.  Seven factors predict a delayed diagnosis of cardiac amyloidosis , 2018, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[15]  C. Rapezzi,et al.  Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths , 2017, European heart journal.

[16]  James C Moon,et al.  Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis , 2016, Circulation.

[17]  F. Salvi,et al.  Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. , 2005, Journal of the American College of Cardiology.

[18]  R A Kyle,et al.  Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. , 1983, The American journal of medicine.